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ABSTRACT
Heart failure (HF) is one of the major problems related to heart diseases in the modern era. Multiple comorbidities such as coronary artery disease, 
hypertension, diabetes mellitus, and anemia have a great contribution in the development of HF. It is primarily two types systolic and diastolic HF. Insufficient 
or decreased pumping of the heart is systolic HF, whereas diastolic HF is because of lack of ability of the heart to relax or increased muscle inflexibility. 
The pathophysiology of HF is due to enhanced activity of sympathetic system, renin angiotensin system, and structural changes in the wall of ventricle. 
The two definite targets of medical treatment in HF are as follows: (1) Alleviation of obstructive (or) decreased output manifestations and replenishment 
of cardiac function. The drugs used are frusemide, thiazides, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), 
amrinone/milrinone, dopamine/dobutamine, levosimendan, digoxin, hydralazine, nitroprusside, nitrate, bisoprolol, metoprolol, nebivolol, and carvedilol. 
(2) Prevention of advancement of HF and extension of patient survival - drugs used are β blockers, ACE inhibitors/ARBs, spironolactone, and eplerenone.
Keywords: Digoxin diuretics Angiotensin converting enzyme inhibitors.
INTRODUCTION
“Heart failure (HF) is a clinical syndrome that occurs in patients 
because of an inherited or acquired abnormality of cardiac structure 
and/or function, clinical symptoms (dyspnea and fatigue), and 
signs (edema and rales) that lead to frequent hospitalizations, a 
poor quality of life, and a shortened life expectancy” [1]. In systolic 
dysfunction (depressed ejection fraction [EF]), heart fails to pump 
the required amount of blood to the body and is characterized by 
an impaired left ventricle (LV) function or low EF, whereas diastolic 
dysfunction (sustained EF) is another kind of cardiac failure where 
the myocardium is unable to accommodate the blood due to failure 
of relaxation or due to muscle stiffening, but here initially the LV 
function is preserved [2].
PATHOPHYSIOLOGY OF HF
Increased activity of sympathetic nervous system
Baroreceptors detect a decrease in blood pressure and trigger the 
activation of β-1 adrenergic receptors in the cardiac tissue resulting 
in the rise of heart rate and cardiac contractility. α-1 adrenergic 
receptors-mediated vasoconstriction enhances the venous return and 
increases preload. The increase in heart rate, contractility, and preload 
initially increases the cardiac output. Vasoconstriction increases the 
afterload and also causes a decrease in EF. Cardiac output finally 
decreases which reduces renal perfusion [3]. Evidence of sympathetic 
activation is due to elevated levels of circulating noradrenaline which 
increases activity in direct sympathetic nerves and finally increases 
noradrenaline release from the heart and other various organs. As 
normal functioning of heart worsens, response to noradrenaline 
decreases due to reduced sensitivity of baroreceptors, down-
regulation of adrenergic receptors in heart, and signal transduction. 
This decreased sensitivity may again trigger the sympathetic response 
in advanced HF patients indicated by decreased cardiac output and 
hypotension. The glomerular filtration rate is reduced, and the Na+ 
and water retention become resistant to treatment with diuretics. 
Increased plasma norepinephrine is related with poor prognosis. 
Other catecholamine role remains unclear [4].
Stimulation of renin–angiotensin aldosterone system (RAAS)
Low cardiac output decreases the blood flow to the kidneys. This 
results in the release of renin, activation of angiotensin II, and release 
of aldosterone [3]. Angiotensin II causes a rise in blood pressure by 
constriction of blood vessels, and it increases glomerular filtration by 
enhancing the renal blood pressure and maintaining the glomerular 
flow. Aldosterone triggers retention of sodium and it reestablishes 
normal cardiac output by increasing intravascular volume [4]. Thus, 
blood volume is increased and there is an increase in preload. Since 
afterload also increases with increase in peripheral vascular resistance, 
the heart is unable to pump the extra volume. The resulting fluid goes 
back to the LV and lungs, then to right ventricle, causing pulmonary 
edema and peripheral edema [3].
Other neurohormonal systems
Elevated circulating and tissue levels of vasodilatory prostaglandins 
improve glomerular hemodynamics. Endothelin, arginine, and 
vasopressin are elevated in many HF patients. Arginine and vasopressin 
induce vasoconstriction through vasopressin-1 (V-1) receptor and 
reduce free water clearance through vasopressin-2 (V-2) receptor. 
Endothelin causes prolonged vasoconstriction, reduction in glomerular 
filtration, and pulmonary arteriolar constriction [1].
Cytokine activation
Circulating levels of cytokines which trigger inflammation such as tumor 
necrosis factor-alpha, interleukin (IL)-1β, and IL-6 are increased in 
relatively severe cardiac failure cases and are involved in the syndrome 
of cardiac cachexia. These cytokines cause contractile dysfunction, 
myocardial fibrosis, and myocyte necrosis and mediate some of the bad 
responses to catecholamines and angiotensin II [4].
Left ventricular remodeling and progression of HF
The most important intrinsic compensatory mechanism is ventricular 
hypertrophy. The LV progressively dilates and changes from the 
normal ellipsoid shape to a more spherical geometry. This cardiac 
remodeling is accompanied by changes in the cardiac interstitium 
that leads to altered orientation of the myofibrils and progressive 
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fibrosis [4]. Cardiac remodeling happens under the influence 
of angiotensin II. Initially, the increase in muscle mass helps to 
maintain the cardiac performance. After the initial beneficial effects 
of hypertrophy, it leads to ischemic changes and alterations in 
ventricular geometry. The ventricular wall tension rises, mechanical 
performance decreases, and blood in both the ventricles is retained 
leading to worsening of cardiac remodeling. Finally, myocytes in the 
failing heart die through apoptosis leaving the remaining myocytes 
with increased workload [4].
The two definite targets of medical treatment in HF are as follows:
A. Alleviation of obstructive (or) decreased output manifestations 
and replenishment of cardiac function. The drugs used are as 
follows:
1. Inotropic agents: Digoxin, dobutamine, dopamine, amrinone, 
milrinone, and levosimendan.
2. Diuretics: Frusemide and thiazides.
3. RAAS inhibiting drugs: Angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs).
4. Vasodilators: Hydralazine, nitrate, and sodium nitroprusside.
5. Beta blockers: Metoprolol, nebivolol, carvedilol, and bisoprolol.
B. Prevention of advancement of HF and extension of patient survival. 
Drugs used are as follows:
1. ACE inhibitors, ARBs, and beta-blockers.
2. Antagonists of aldosterone are spironolactone and eplerenone.
DIGOXIN
Mechanism of action
With each cardiac myocyte depolarization, sodium and calcium 
ions shift into the intracellular space. Calcium enters the cell 
through the L-type Ca2+ channel during depolarization triggers 
the release of stored intracellular Ca2+ from the sarcoplasmic 
reticulum (SR) through the ryanodine receptor. This increases 
the level of cytosolic Ca2+ available for interaction with myocyte 
contractile proteins and increases myocardial contraction force. 
During myocyte repolarization and relaxation, Ca2+ present in the 
cell is resequestered by the sarcoplasmic reticular Ca2+-ATPase 
(SERCA2) and is eliminated by the Na+-Ca2+ exchanger and to a 
lesser extent, by the sarcolemmal Ca2+-ATPase. Digoxin binds and 
inhibits the phosphorylated subunit of the sarcolemmal Na+K+-
ATPase, thereby decreasing Na+ extrusion and increasing cytosolic 
Na+. This decreases the transmembrane Na+ gradient that drives 
Na+–Ca2+ exchange during myocyte repolarization. As a result, 
less Ca2+ is removed from the cell and more Ca2+ is accumulated 
in the SR by SERCA2. This increase in releasable Ca2+ (from the SR) 
is the primary mechanism by which digoxin enhances myocardial 
contractility [5].
Other effects of digoxin [6]
1. Digitalis increases peripheral resistance in normal individuals due 
to vasoconstriction. However, in HF patients, reflex sympathetic 
overactivity is withdrawn, and hence, peripheral resistance 
decreases.
2. Diuresis occurs in HF patients due to improvement in circulation 
and renal perfusion.
3. In higher doses digoxin causes nausea, vomiting, and central 
sympathetic stimulation.
Pharmacokinetics of digoxin [6]
1. Oral absorption: 60–80%.
2. Binding to the proteins within plasma: 25%.
3. Time track of drug action:
• Onset of action: 15–30 min.
• Optimum levels attained in 2–5 h.
• Period of action: 2–6 days.
4. Plasma half-life: 40 h.
5. Therapeutic action: 0.5–1.4 ng/mL.
6. Toxic concentration: >2 ng/mL.
7. Daily maintenance dose: 0.125–0.5 mg.
8. Daily elimination: 35%.
9. Route of elimination: Renal.
10 Route of administration: Oral, intravenous.
Adverse effects of digoxin [6]
Extracardiac: Anorexia, nausea, vomiting and abdominal pain, fatigue, 
feeling of uneasiness, hyperpnoea, severe mental disorders, and vision 
problems.
Cardiac: Pulsus bigeminus, ventricular extrasystoles, ventricular 
tachycardia, atrioventricular block, and bradycardia.
Contraindications of digoxin [6]
1. Hypokalemia: Enhances digitalis toxicity.
2. Aged people, patients with kidney or liver ailments: More susceptible 
to digoxin toxicity.
3. Myocardial ischemia: Severe arrhythmias.
4. High risk of digitalis arrhythmias in thyrotoxicosis patients.
5. Patients with myxedema excrete digoxin slowly.
6. Digitalis is contraindicated in ventricular tachycardia because it may 
provoke ventricular fibrillation.
7. Partial atrioventricular block may be converted to complete 
atrioventricular block by digoxin.
8. Acute myocarditis: Inotropic response to digitalis is less and also 
there is risk of arrhythmias.
9. Wolff–Parkinson–White syndrome: Digitalis is not given.
Interactions of digoxin [6]
1. Diuretics: Cause hypokalemia which increases the risk of digitalis 
arrhythmias.
2. Calcium and digitalis combination has synergistic effect which is 
dangerous.
3. Quinidine minimizes coupling of digoxin with tissue proteins and 
also decreases biliary and renal elimination by suppressing efflux 
transporter P-glycoprotein causing doubling of plasma levels of 
digoxin resulting in toxicity.
4. Adrenergic drugs: Can provoke arrhythmias in digitalis taking 
individuals.
5. Absorption of digoxin may be diminished by sucralfate, antacids, 
neomycin and sulfasalazine, and metoclopramide.
6. Tricyclic antidepressants enhance the absorption of digoxin.
7. Succinylcholine: Can induce arrhythmias in digitalized patients.
Dosage of Digoxin
In mild–to-moderate HF, digoxin therapy is initiated with the estimated 
maintenance doses (0.125–0.25 mg/day) without any loading dose. 
Full response takes 5–7 days. In case of inadequate response, the dose 
is increased to 0.375 and 0.5 mg/day at weekly intervals. Diminution 
in heart rate and relief of HF symptoms are the best guide for dosing. 
Current data suggest that using of submaximal inotropic doses (causing 
steady-stage digoxin concentrations <1 ng/mL) in maintenance therapy 
may have the advantage by opposing neurohormonal triggering of 
congestive HF (CHF) with no toxicity [6].
Key evidence in trials
1. In the digitalis investigation group study, patients having EF ≤45% 
and in the New York Heart Association (NYHA) functional Class II–IV 
were randomly allocated to placebo or digoxin (dose 0.25 mg OD 
[once daily]) given along with an ACE inhibiting drug and a diuretic. 
28% decrease in cardiovascular death was observed within 3 years 
of starting the drug [7].
2. Two large studies - “randomized assessment of digoxin on inhibition 
of ACE” and - “prospective randomized study of ventricular failure 
and efficacy of digoxin” on CHF patients in sinus rhythm revealed 
that stopping of digitalis showed decreased capacity of exercise and 
hemodynamic worsening in a considerable subset of patients even 
after the use of diuretic without discontinuation and with or without 
ACE inhibitor [6].
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DOPAMINE
Dopamine is an endogenous catecholamine with only limited use 
in the therapy of most cases with cardiogenic circulatory failure. 
The pharmacologic and hemodynamic effects of dopamine are 
concentration dependent. Low doses (2 mcg/kg lean body mass/min) 
induce vascular smooth muscle vasodilation (predominantly renal) 
and cause activation of D2 receptors on sympathetic nerves in the 
peripheral circulation. It also inhibits norepinephrine release and 
reduces adrenergic stimulation of vascular smooth muscle particularly 
in splanchnic and renal arterial beds. Therefore, low-dose dopamine 
infusion is often used to increase renal blood flow and thereby 
maintains an adequate glomerular filtration rate in hospitalized 
CHF patients with impaired renal function refractory to diuretics. 
Dopamine also exhibits a pro-diuretic effect directly on renal tubular 
epithelial cells that contribute to volume reduction. At intermediate 
infusion rates (2–5 mcg/kg/min), dopamine directly stimulates 
cardiac receptors (β1) and vascular sympathetic neurons that enhance 
myocardial contractility and neural NE (norepinephrine) release. 
At higher infusion rates (5–15 mcg/kg/min), adrenergic receptor 
stimulation (α1) mediated peripheral arterial and venous constriction 
occurs. However, high-dose dopamine infusion has little role in the 
treatment of patients with primary cardiac contractile dysfunction. 
Increased vasoconstriction will lead to increased afterload and 
worsening of LV performance [5].
DOBUTAMINE
In the treatment of CHF patients with systolic function impairment, 
dobutamine is the β-agonist of choice. It results in a positive inotropic 
effect in humans by stimulating the β1 adrenergic receptor in the 
myocardium. Thus, the principal hemodynamic effect of dobutamine 
is an increase in stroke volume due to positive ionotropy. Continuous 
dobutamine infusions are typically initiated at 2–3 g/kg/min without a 
loading dose and uptitrated until the desired hemodynamic response is 
achieved. Pharmacologic tolerance may limit infusion efficacy beyond 
4 days and addition or substitution with a Class III phosphodiesterase 
(PDE) inhibitor may be necessary to maintain adequate circulatory 
support. The major side effects of dobutamine are tachycardia, 
supraventricular, or ventricular arrhythmias which may require a 
reduction in dosage [5].
PDE INHIBITORS
Inamrinone and milrinone
The cyclic adenosine monophosphate phosphate (cAMP) - PDE 
inhibitors decrease cellular cAMP degradation resulting in increased 
concentrations of cAMP in cardiac and smooth muscle myocyte. 
The physiologic effects of this are positive myocardial inotropism 
and dilation of resistance and capacitance vessels. PDE inhibition 
improves cardiac output through inotropy and by decreasing preload 
and afterload. Parenteral formulations of inamrinone and milrinone 
are approved for short-term circulation support in advanced CHF. As a 
result of its effect on LV contractility, the increase in cardiac output due 
to milrinone is superior to nitroprusside despite a comparable decrease 
in systemic vascular resistance. The arterial and venodilatory effects of 
milrinone are prominent than those of dobutamine at concentrations 
that cause almost identical increases in cardiac output. For inamrinone, 
a 0.75-mg/kg bolus injection given over 2–3 min is typically followed by 
a 2–20 mcg/kg/min infusion [5].
Sildenafil
In contrast to inamrinone and milrinone, sildenafil inhibits PDE5 
which is the most common PDE isoform in lung tissue. The primary 
clinical application of sildenafil in CHF has mainly been limited to 
those with isolated right ventricular systolic failure from pulmonary 
artery hypertension [5]. However, recently published reports suggest 
that sildenafil favorably influences capacity of exercise and right-heart 
hemodynamics in pulmonary hypertensive patients from LV systolic 
dysfunction as well [8].
LEVOSIMENDAN
Levosimendan exerts vasodilatory properties through activation of 
K+-ATP (ATP-dependent potassium channels) in smooth muscles of 
pulmonary, coronary, and peripheral vessels with a unique mechanism 
of action. It enhances myofilament responsiveness to calcium by 
binding to cardiac troponin C. This stabilizes the tropomyosin 
molecule and prolongs the period of actin-myosin sliding with no 
effect on intracellular calcium levels and with no increasing myocardial 
oxygen consumption [9]. It also activates K+-ATP channels which are 
important mediators of ischemia and reperfusion injury, results in 
coronary vasodilatation to improve heart oxygenation, and shows 
protective effects on the myocardium [10]. Thus, they decrease both 
preload and afterload, increase coronary circulation, and result in anti-
ischemic effect. It is classified as an inotropic agent with anti-ischemic 
property [11].
DIURETICS
Loop diuretics (high ceiling diuretics)
Loop diuretics inhibit Na+-K+-2Cl– symporter on the apical membrane 
of renal epithelial cells in the ascending limb of the Henle’s loop and 
increase sodium, fluid delivery to distal nephron segments. These drugs 
also augment K+ secretion, particularly in the presence of increased 
aldosterone concentrations. High ceiling diuretics such as frusemide, 
bumetanide, and also torsemide are commonly utilized in CHF 
management. The bioavailability of orally administered furosemide 
ranges from 40% to 70% [5].
Thiazides
Monotherapy with thiazide diuretics has a limited role in CHF. However, 
combination therapy with loop diuretics is often effective in those 
refractory to loop diuretics alone. Thiazide diuretics act on the Na+Cl– 
cotransporter in the distal convoluted tubule and are associated with 
a greater degree of K+ wasting per fluid volume reduction when 
compared to high ceiling diuretics [5].
Potassium sparing diuretics
These drugs inhibit apical membrane Na+-conductance channels in 
renal epithelial cells or act as mineralocorticoid (e.g., aldosterone) and 
receptor antagonists (e.g., canrenone, spironolactone, and eplerenone). 
These agents are weak diuretics but have historically been used to 
achieve volume reduction with limited K+ and Mg2+ wasting [5]. Refer 
to Table 1 for dosage of various diuretics.
Key features of diuretic usage in clinical practice
1. Two major roles of diuretic: (a) Reduce preload and enhance 
ventricular working ability by decreasing the circulatory volume 
and (b) reduce peripheral accumulation of fluid and also pulmonary 
congestion [6].
2. In cases having obvious fluid accumulation, frusemide is given at 
a dose of 40 mg or BD (twice daily), and then, dose is raised until 
requisite diuresis is attained. Serum electrolytes and renal function 
are often monitored in these cases or in those for whom a rapid 
diuresis is necessary[5].
3. In patients with decompensated CHF warranting hospital admission, 
repetitive intravenously administered boluses or a constant infusion 
titrated to achieve a desired response may be needed to provide 
expeditious diuresis [12].
4. Studies have demonstrated that the diuretics can enhance excretion 
of Na+ in urine and minimize physical manifestations of fluid 
accumulation in cases of HF [13].
5. Several studies have shown diuretics to relieve symptoms and 
increase exercise capacity in HF patients [14].
6. Diuretics are given together with an ACE inhibiting drug, aldosterone 
antagonist, and β blocker. Without the use of diuretics, some HF 
patients not able to maintain target weight [15].
7. Diuretics are usually given along with moderate reduction in 
dietary sodium. If patients are taking high quantities of sodium in 
diet or consume medication that can reduce the action of diuretics 
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(e.g., NSAIDs), then they may become refractory to increased doses 
of diuretics [15].
8. Resistance to diuretics can be overcome by giving diuretics through 
intravenous route or combining drugs from different diuretic 
classes [15].
9. Diuretics side effects are fluid reduction, electrolyte imbalance, 
hypotension, hypokalemia, hypomagnesaemia, and azotemia [15].
10. A retrospective study conducted by us demonstrated that while 
patient admission, the extent of prescription of loop diuretics was 
high for left ventricular systolic dysfunction cases than preserved 
systolic function ones [16].
DRUGS ACTING ON RENIN–ANGIOTENSIN SYSTEM
ACE inhibitors
These drugs inhibit the conversion of non-functioning decapeptide 
angiotensin I to the active octapeptide angiotensin II by inhibiting 
the ACE. Excessive angiotensin II causes stimulation of angiotensin II 
type 1 receptor subtype (AT1R) resulting in vasoconstriction 
(increases ventricular afterload), excessive growth of myocyte, left 
ventricular remodeling, stimulation of the sympathetic nervous 
system, prothrombotic actions, arginine vasopressin (AVP) release, 
and retention of sodium. ACE inhibitors also decrease the breakdown 
of bradykinin leading to accumulation of bradykinin which is 
responsible for adverse drug reactions of ACE inhibitors (cough and 
angioedema) [17]. Refer to Table 2 for dosage of various ACE inhibitors.
Key evidence in trials
1. Two trials which are randomized controlled studies such 
as Cooperative North Scandinavian Enalapril Survival Study 
(CONSENSUS) and studies of left ventricular dysfunction (SOLVD) 
treatment randomly allocated HF subjects who were having 
mild-to-severe symptoms to placebo or enalapril. Results of these 
studies demonstrated that management with enalapril decreased 
the cardiovascular-related death in both CONSENSUS and SOLVD 
treatment by 27% and 16%, respectively [18,19].
2. Within 3 months duration, treatment with ACE inhibitors in small 
placebo-controlled RCTs demonstrated a significant decrease in 
cardiovascular-related death [20].
3. In the “assessment of treatment with lisinopril and survival” (ATLAS) 
study, 3164 HF cases having moderate-to-severe symptoms were 
given lisinopril in low or high dose. Lisinopril group with high dose 
was differentiated from low dose by 15% decrease in mortality or 
hospitalization due to HF [21].
4. SOLVD prevention study demonstrated 20% decrease in mortality 
or hospitalization due to HF [22].
5. ACE inhibiting drugs should only be given in cases having appropriate 
functioning of kidney (creatinine ≤ 221mmol/L or ≤2.5 mg/dL or 
eGFR ≥30 mL/min/1.73 m2) and adequate serum K+ levels [23].
Indications of ACE inhibitors [17]
1. Patients having HF and a reduced EF.
2. In NYHA Class II-IV, HF patients as a first-line therapy in conjunction 
with β-blockers.
3. Patients having left ventricular systolic function impairment without 
symptoms (NYHA Class I).
ARBs
These drugs prevent the binding of angiotensin II with AT1R. ARBs are 
not involved in inhibition of kinase II or the degradation of bradykinin, 
so there is no cough and no significant angioedema compared to ACE 
inhibitors [17]. Refer to Table 3 for dosage of various ARBs.
Key evidence in trials
1. Two placebo-controlled RCTs, Val-HeFT - “Valsartan HF trial” and 
CHARM-added - “candesartan in HF assessment of reduction in 
mortality and morbidity-added” randomly allocated cases having 
mild–to-severe HF symptoms to placebo or an ARB, given along with 
an ACE inhibitor. These Val-HeFT and CHARM-added studies showed 
decreased risk of hospitalization associated with HF by 24% and 
17%, respectively, but not the risk associated with rehospitilization. 
The same studies also demonstrated that ARBs caused improvement 
of symptoms and quality of life [24,25].
2. CHARM alternative study involving candesartan including 2028 cases 
who were having left ventricular EF (LVEF) ≤40% (do not tolerate 
ACE inhibiting drugs) showed 23% decrease in mortality or HF 
hospitalization [26]. Valsartan also has a useful effect in certain cases 
(patients not treated by ACE inhibiting drugs) of Val-HeFT [27].
3. One more study, “evaluation of losartan in the elderly II” was failed in 
demonstrating that 50 mg once in a day dose of losartan was equal 
efficacious as 50 mg thrice in a day dose of captopril [28]. Later, 
studies such as “HF Endpoint evaluation of angiotensin II antagonist 
losartan (HEAAL)” demonstrated that losartan 150 mg once in a day 
was effective than 50 mg once in a day and supported results of the 
ATLAS study with the lisinopril [29]. In HEAAL trial, high-dose losartan 
group showed 10% decrease in mortality or HF hospitalization. These 
ATLAS and HEAAL studies showed that better results were achieved 
by administering larger doses of lisinopril and losartan [28].
Prescription of ARB’s was more in cases of preserved systolic function 
than left ventricular systolic dysfunction during patient admission as 
well as discharge [16].
Indications of ARBs [5]
1. All patients with HF.
2. In NYHA class II-IV HF cases who are intolerant to ACE inhibitor.
3. Second-line management following optimization of ACE inhibiting 
drug and β-blocker in cases of NYHA Class II–IV HF.
RENIN INHIBITORS
“Aliskiren” is the first orally administered direct inhibitor of renin 
to receive approval from the FDA. Pilot clinical trials in humans 
established that aliskiren induces a concentration-dependent decrease 
in plasma renin activity in Angiotensin I and Angiotensin II levels that 
were associated with a decrease in systemic blood pressure without 
significant reflex tachycardia [30]. The safety profile of aliskiren in CHF 
was established recently by the ‘Aliskiren Observation of Heart Failure 
Treatment’ study. Aliskiren was given at a dose 150 mg/day as adjunct 
treatment in the trial. Outcome from this trial also demonstrated 
that compared to placebo, aliskiren significantly decreased plasma 
N-terminal-proBNP levels, a clinically useful neurohumoral biomarker 
of active CHF. These findings affirm that inhibition of renin activity is 
an important potential target for decreasing symptoms and increasing 
functional capacity in CHF [31]. However, available data on aliskiren 
and its efficacy in management of CHF are less because well-organized 
RCT (Randomized controlled trials) are not yet conducted.
BETA-BLOCKERS
Research and trials in previous 30 years have confirmed the usefulness 
of β1-blockers (primarily bisoprolol, metoprolol, nebivolol) and 
carvedilol in patients of mild-to-moderate symptomatic CHF who 
were treated by ACE inhibiting drugs ± diuretic and digitalis. 
Although β-blockers instantly reduce contractility of the heart and 
EF, progressive improvement in these features occurs over weeks. 
Few months later, EF is greater than baseline and gradual incremental 
doses further improve cardiac function. The advantages of β blockers 
are said to be due to opposing effects on increasing ventricular wall 
stress, stimulation of apoptosis, and abnormal remodeling changes 
of sympathetic overactivity in CHF, in addition to minimization of the 
occurrence of dangerous arrhythmias. The occurrence of unexpected 
cardiac associated deaths as well as deterioration of CHF is reduced. 
Beta-blockers decrease plasma markers of stimulation of sympathetic 
system, renin-angiotensin systems, and also endothelin-1 [17]. Refer to 
Table 4 for dosage of various beta blockers.
Key evidence in trials
1. Studies such as - “cardiac insufficiency bisoprolol study 
II,” - “carvedilol prospective randomized cumulative survival,” 
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and merit-HF - “metoprolol CR/XL randomized intervention trial 
in CHF” randomized subjects having mild-to-severe symptoms of 
HF to placebo or a beta receptor blocker (bisoprolol, carvedilol, or 
metoprolol succinate CR/XL). more than 90% of the subjects received 
an ACE inhibiting drug or ARB. Results of these studies demonstrated 
that there was 34% decrease in mortality in each trial and 28–36% 
decrease in HF hospitalization by treatment with β-blocker within 
a year of introduction of therapy [32-36].
2. One more study, “evaluation of losartan in the elderly II” failed to 
demonstrate that 50 mg once in a day dose of losartan was equally 
efficacious as 50 mg thrice in a day dose of captopril [37].
3. US carvedilol studies and meta-analysis of some minitrials 
involving β-blockers showed 23% decrease in mortality by using 
carvedilol [38].
4. A randomized control trial such as “beta-blocker evaluation of 
survival trial” involving bucindolol failed to show a considerable 
decrease in mortality [39].
5. “Carvedilol Or Metoprolol European trial” demonstrated that 
treatment with carvedilol has better survival rate than short-acting 
metoprolol tartrate [40].
6. Another study suggested that carvedilol in combination with 
conventional therapy has increased the patient survival rate 
and decreased the hospitalization rate when compared to 
Metoprolol [41].
Indications of beta-blockers [5]
1. Stable mild-to-moderate HF cases.
2. Stable NYHA Class II–III cardiac failure cases as a first-line treatment 
with ACE inhibitors.
ALDOSTERONE ANTAGONISTS
In CHF patients, there is an increase in aldosterone levels in plasma, 
and its’ established function of sodium and water retention has a major 
role in disease advancement. Various factors contributing to worsening 
of CHF include: (a) Increase in extracellular fluid volume→raise in 
preload, (b) fibroblast proliferation and fibrous connective tissue 
deposition in myocardium→deterioration of systolic function and 
harmful remodeling effects, (c) decline in potassium and magnesium 
levels→raise in possibility of ventricular arrhythmias, unexpected 
cardiac associated death, and (d) augmentation of cardiotoxic 
and remodeling changes of excessive sympathetic stimulation. 
Spironolactone, it has aldosterone antagonistic and also weak 
diuretic action. It is useful in CHF by antagonizing the above actions 
of aldosterone. It may be useful in reestablishment of diuretic action 
to frusemide when the response of frusemide is attenuated [17]. 
Eplerenone in combination with conventional therapy is usually 
prescribed for HF as well as left ventricular dysfunctioning patients to 
decrease the cardiovascular mortality [42]. Refer to Table 5 for dosage 
of various aldosterone antagonists.
Key evidence in trials
1. The “randomized aldactone evaluation study” (RALES) was 
conducted by giving spironolactone to subjects having severe 
HF. In this study, subjects having EF ≤35% and NYHA functional 
class III (having been in class IV within the previous 6 months) were 
randomly allocated to placebo or 25–50 mg dose of spironolactone 
once in a day. Results showed 30% decrease in mortality and 
35% decrease in HF hospitalization within 2 years of introducing 
therapy [43].
2. In EMPHASIS-HF study (patients aged ≥55 years with NYHA 
functional class II symptoms and an EF ≤30%), subjects who were 
administered with eplerenone of dose up to 50 mg once in a day 
showed 37% decrease in mortality or HF hospitalization and benefits 
were acquired within 21 months of introducing therapy [44]. 
3. One more RCT, “eplerenone post-acute myocardial infarction HF 
efficacy and survival study,” including subjects 3–14 days after acute 
myocardial infarction having EF≤40% and HF or diabetes. Subjects 
were randomly allocated to placebo or 25–50 mg dose of eplerenone 
once in a day given along with conventional treatment. Results 
demonstrated 15% decrease in cardiovascular-related death with 
eplerenone [45].
Indications of aldosterone antagonists [17]
1. HF cases having symptoms (Class II-IV NYHA).
2. Second-line treatment (following ACE inhibitors and β-blockers) in 
patients with NYHA Class II–IV HF.
VASODILATORS
Vasodilators were first used intravenous for treating sudden cardiac 
failure which usually takes place in severe cases. Their use by oral route 
has been extended to long-term therapy of persistent CHF. Vasodilators 
other than ACE inhibitors/ARBs have only limited utility. Nitrates 
promote accumulation of blood in veins, resulting in reduce preload 
(reduction in ventricular end diastolic pressure and volume). Hence 
decrease in size and volume of ventricles, results in decrease in cardiac 
work (according to law of laplace, the tension upon the muscle fibers 
in the heart wall is the pressure within the ventricle multiplied by the 
ventricular radius) and better ventricular emptying during systole. 
Hydralazine causes dilation of resistance vessels and decreases the 
impedance of aorta, and hence, even weaker contraction of ventricle 
can eject large amount of blood and systolic wall stress is decreased. 
It is effective in forward failure when cardiac index (CI=min output/
body surface area) is low (<2.5 L/min/m2) without a significant rise in 
central venous pressure [17].
Key evidence in trials
1. In “Vasodilator HF Trial-I” (V-HeFT-I), subjects were randomly 
allocated to placebo, prazosin, or hydralazine-isosorbide Dinitrate 
(H-ISDN) given along with diuretic plus digoxin. Patients were not 
treated with a beta-blocker or an ACE inhibitor. In H-ISDN group, 
22% decrease in all-cause mortality, but there was no significant 
variation in mortality rates in other groups [46].
2. In the African-American Heart Failure Trial (A-HeFT), both men 
and women from Africa and America with NYHA class III or IV were 
randomly allocated to placebo or H-ISDN added to a diuretic (90%), 
digoxin (60%), ACE inhibitor (70%), ARB (17%), beta-blocker (74%), 
and spironolactone (39%). The starting dose of therapy was 20 mg 
ISDN/37.5 mg hydralazine 3 times in a day and increased to a target 
of 40 mg/75 mg 3 times in a day. Results showed 43% decrease in 
cardiovascular-related death and 33% decrease in the risk associated 
with HF hospitalization [47]. 
3. In V-HeFT-II, subjects were randomly allocated to enalapril or H-ISDN 
given along with diuretic plus digoxin. Results showed a rise in all-
cause mortality throughout the follow-up period (mean 2.5 years) 
and H-ISDN group showed 28% relative hike in risk [48].
Nitrates, inotropic drugs, and ACE inhibitors usage were more in 
cases of left ventricular systolic dysfunction than preserved systolic 
function [16].
VASOPRESSIN ANTAGONISTS
In response to serum hypertonicity induced activation of anterior 
pituitary osmoreceptors and a perceived drop in blood pressure 
detected by baroreceptors in the carotid artery, aortic arch and left 
atrium, AVP ae secreted into the systemic circulation. The AVP-V2 
receptor interaction on the basolateral membrane of the collecting 
ducts of kidney stimulates synthesis of aquaporin-2 water channels 
that mediate free water reabsorption, thereby impairing diuresis and 
correcting plasma hypertonicity. Additional cell signaling pathways 
important in the pathophysiology of CHF include vasoconstriction, cell 
hypertrophy, and increased platelet aggregation mediated by activation 
of V1a receptors present in smooth muscle cells of blood vessels and 
cardiac myocytes. In addition, angiotensin II-mediated activation 
of centrally located AT1 receptors is associated with increased AVP 
levels in CHF and may represent one mechanism by which AT1-
receptor antagonists are effective in the clinical management of these 
patients [17]. Conivaptan has dual vasopressin receptor antagonistic 
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edema. Hyponatremia patients showed a prominent rise in Na+ 
concentration [52,53].
IVABRADINE
Ivabradine is a novel agent which particularly decreases heart rate by 
altering electrical currents in the sinus node. It is an inhibitor of the If 
current [54] in the SA-node leading to a decrease in heart rate without 
affecting blood pressure, contractility, and other aspects of intracardiac 
conduction. In LV systolic dysfunction and coronary artery diseases, 
this drug is used [55].
Key evidence in trials
1.  The ”systolic HF treatment with the If inhibitor ivabradine trial” 
enrolled subjects of NYHA functional class II–IV and having sinus 
rhythm of rate ≥70 beats per min, EF ≤35%. Patients were randomly 
allocated to ivabradine (uptitrated to a maximal dosage of 7.5 mg 
function, and it causes increase in output of urine and decreases both 
pulmonary capillary wedge pressure and pressure in right atrium in 
systolic HF patients when compared to placebo [49]. Tolvaptan, which 
is an antagonist of a V1a receptor, also promotes a rise in output of 
urine and reduce body weight without a remarkable change in kidney 
function [50,51]. Refer to Table 6 for dosage of various vasodilators
Key evidence in trials
1. “Efficacy of vasopressin antagonism in heart failure outcome 
study with tolvaptan” study, involved subjects of those who were 
hospitalized for deteriorating cardiac failure and reduced LV 
efficiency (EF<40%). Subjects were randomized to oral tolvaptan 
or placebo. After a median follow-up duration of 9.9 months, it was 
observed that no variation in the all-cause mortality and death 
from cardiovascular etiology or HF hospitalization. However, there 
were improvements in patient-assessed dyspnea, body weight, and 
Table 1: Dose and duration of oral diuretics [15]
Drug Dialy dose (initial) Maximum total daily dose Duration of action
High ceiling diuretics
1. Bumetanide 0.5–1.0 mg OD or BD 10 mg 4–6 h
2. Furosemide 20–40 mg OD or BD 600 mg 6–8 h
3. Torsemide 10–20 mg OD 200 mg 12–16 h
Thiazide diuretics
1. Chlorothiazide 250–500 mg OD or BD 1000 mg 6–12 h
2. Hydrochlorothiazide 25 mg OD or BD 200 mg 6–12 h
3. Indapamide 2.5 mg OD 5 mg 36 h
4. Metolazone 2.5 mg OD 20 mg 12–24 h
Potassium-sparing diuretics
1. Amiloride 5 mg OD 20 mg 24 h
2. Spironolactone 12.5–25 mg OD 50 mg 1–3 h
3. Triamterene 50–75 mg BD 200 mg 7–9 h
Sequential nephron blockade
1. Metolazone 2.5–10 mg OD+high ceiling diuretic
2. Hydrochlorothiazide 25–100 mg OD+high ceiling diuretic
3. Chlorothiazide (IV) 500–1000 mg OD+high ceiling 
diuretic
Drug Dialy dose (initial) Maximum total daily dose Duration of action
High ceiling diuretics
1. Bumetanide 0.5–1.0 mg OD or BD 10 mg 4–6 h
2. Furosemide 20–40 mg OD or BD 600 mg 6–8
3. Torsemide 10–20 mg OD 200 mg 12–16 h
Thiazide diuretics
1. Chlorothiazide 250–500 mg OD or BD 1000 mg 6–12 h
2. Hydrochlorothiazide 25 mg OD or BD 200 mg 6–12 h
3. Indapamide 2.5 mg OD 5 mg 36 h
4. Metolazone 2.5 mg OD 20 mg 12–24 h
Potassium-sparing diuretics
1. Amiloride 5 mg OD 20 mg 20 mg
2. Spironolactone 12.5–25 mg OD 50 mg 1–3 h
3. Triamterene 50–75 mg BD 200 mg 7–9 h
Sequential nephron blockade
1. Metolazone 2.5–10 mg OD+high ceiling diuretic
2. Hydrochlorothiazide 25–100 mg OD+high ceiling diuretic
3. Chlorothiazide (IV) 500–1000 mg OD+high ceiling 
diuretic
OD: Once daily
Table 2: Dosage of ACE inhibitors [5,15]
Drug Initial daily dose Maximum dose Maximum dose achieved in clinical trials
1. Captopril 6.25 mg TID (3 times in a day) 50 mg TID 122.7 mg/day
2. Enalapril 2.5 mg BD 10–20 mg BD 16.6 mg/day
3. Fosinopril 5–10 mg OD 40 mg
4. Lisinopril 2.5–5 mg 20–40 mg 32.5–35 mg/day
5. Perindopril 2 mg OD 8–16 mg OD
6. Quinapril 5 mg BD 20 mg BD
7. Ramipril 1.25–2.5 mg OD 10 mg OD
8. Trandolapril 1 mg OD 4 mg OD
ACE: Angiotensin-converting enzyme
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2 times in a day) or placebo and added to a diuretic (in 84%), digoxin 
(22%), an ACE inhibitor (79%), an ARB (14%), a beta-blocker (90%), 
and a MRA (60%). Results showed 18% decrease in mortality and 
26% decrease in the risk of HF hospitalization [56].
2.  Evaluation of the If inhibitor ivabradine patients with coronary 
disease and left ventricular dysfunction (BEAUTIFUL) in which 
subjects having coronary heart disease and an EF<40% was received 
ivabradine 7.5 mg 2 times in a day or placebo. Ivabradine failed to 
decrease the myocardial infarction, cardiovascular-related death, 
and HF hospitalization but it was well tolerated [57].
STATINS
Statins are inhibitors of HMG-CoA reductase enzyme [58] show various 
beneficial cardiovascular effects in addition to LDL (low-density lipid) 
reduction. Statins are associated with positive LV remodeling, increased 
arteriolar blood flow, and decreased circulating platelet aggregation. 
Intermediate by-products of mevalonate metabolism are linked to 
impaired vascular function by increasing levels of oxidant stress 
and decreasing bioavailable nitric oxide levels. Statins inhibit these 
intermediary pathways and appear to restore endothelium-dependent 
and endothelium-independent vascular function [5].
Key evidence in trials
1. CORONA trial enrolled patients of age ≥60 years who were having 
HF symptoms (NYHA class II– IV) of ischemic etiology and EF 
≤40%. Rosuvastatin failed to decrease stroke, mortality, myocardial 
infarction, and all-cause mortality [59].
2. In the GISSI-HF statin study, subjects who were having HF symptoms 
(NYHA class II–IV) of both ischemic as well as non-ischemic origin 
were enrolled. Patients had an EF ≤40% and were randomly allocated 
to placebo or rosuvastatin 10 mg once in a day. Rosuvastatin failed 
to decrease all-cause mortality and hospitalization [60].
OMEGA-3-FATTY ACIDS
The small treatment effect of n-3 polyunsaturated fatty acids (PUFAs) in the 
Gruppo Italiano per lo Studio dellaSopravvivenza nell’Infarto miocardico-
HF (GISSI-HF) study demonstrated no effect on HF hospitalization [61].
ADENOSINE ANTAGONISTS
Adenosine receptors (A1) are present in the renal afferent arteriole and 
proximal convoluted tubule. They are involved in constriction of these 
arterioles and tubuloglomerular feedback [62,63]. In cardiac failure 
patients, increase in Na+ levels in the distal tubule stimulates a feedback 
mechanism to the macula densa resulting in the release of adenosine which 
causes augmentation in sodium reabsorption by the proximal convoluted 
tubule and constriction of afferent arterioles, resulting in lowering of 
filtering capacity of kidney [63]. Hence, these drugs significantly increase 
natriuresis in HF without altering renal function [64].
Key evidence in trials
1. In the pilot phase of the placebo-controlled randomized control trial 
of the drug rolofylline which is a antagonist of selective A1 adenosine 
receptor, enrolled subjects were hospitalized cases with sudden cardiac 
failure were randomly allocated to be given one of three doses of 
rolofylline or placebo. Rolofylline recipients showed a decrease in 60-
day mortality and readmission for cardiovascular or renal cause and 
lesser increase in serum creatinine level [65,66].
ULARITIDE
Ularitide binds to natriuretic peptide receptors located on medullary 
collecting duct cells and vascular smooth muscle cells, which 
leads to increased diuresis, natriuresis, and arterial and venous 
vasodilation [67]. Clinically, ularitide has been shown to induce 
natriuresis and at the same time decrease plasma concentrations of 
renin, aldosterone, and angiotensin II [68,69].
Key evidence in trials
1.  In the “safety and efficacy of an intravenous placebo-controlled 
randomized infusion of Ularitide”-II trial, 221 patients with HF were 
randomly given one of three doses of ularitide or placebo in addition 
to baseline loop and thiazide diuretics. Subjects treated with ularitide 
exhibited an improvement in dyspnea and hemodynamic parameters. 
A trend toward improved rates of 30-day mortality was noted in the 
ularitide recipients. The most common side effect of ularitide was 
hypotension which was most prominent with the highest dose. No 
significant worsening of renal function was noted [70].
ISTAROXIME
Istaroxime is a contractility-enhancing agent that inhibits sodium-
potassium ATPase and increases the activity of SERCA. Increased 
SERCA activity results in accumulation of calcium within the myocyte 
during systole and rapid extrusion of calcium in diastole which lead to 
an improvement in both inotropic function [55].
Key evidence in trials
1.  A phase II study of Effects of Istaroxime in subjects having 
deteriorating HF and decreased LV Systolic Function (HORIZON-HF) 
showed a significant decrease in pulmonary capillary wedge pressure 
in comparison to placebo. Prominent reduction in heart rate and a 
raise in systolic blood pressure was noted. Prominent reduction in 
heart rate and a raise in systolic blood pressure wee noted. Patients 
with the highest dose showed an increase in CI, a decrease in left 
ventricular end-diastolic volume, and improvement in diastolic 




By inhibiting carnitine palmitoyltransferase-1 enzyme, perhexiline 
reduces mitochondrial FFA transport that causes increased glucose 
metabolism [72]. A small trial of 56 subjects having chronic NYHA 
Table 3: Dosage of ARBs [23]
Drug Initially daily dose Maximum dose Mean dose achieved in clinical trials
1. Candesartan 4–8 mg once 32 mg once 24 mg/day
2. Losartan 25–50 mg once 50–150 mg once 129 mg/day
3. Valsartan 20–40 mg twice 160 mg twice 254 mg/day
ARBs: Angiotensin receptor blockers
Table 4: Dosage of beta blockers [15]




1. Bisoprolol 1.25 mg OD 10 mg OD
2. Carvedilol 3.125 mg BD 50 mg BD




12.5–25 mg OD 200 mg OD
Table 5: Dosage of aldosterone antagonists [15]
Drug Initial daily dose Maximum dose
1. Spironolactone 12.5–25 mg once 25 mg once or twice
2. Eplerenone 25 mg/day 50 mg once
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functional Class II or III systolic cardiac failure were randomly allocated 
to perhexiline or placebo administration. After 8 weeks, perhexiline-
treated cases showed a remarkable improvement in left ventricular 
function along with increased oxygen utilization during exercise in 
contrast to the placebo group [73].
Trimetazidine
This drug inhibits long-chain 3-ketoacyl coenzyme A thiolase, and 
this enzyme has a crucial role in free fatty acid oxidation, resulting in 
increased utilization of myocardial glucose [74]. Fragasso et al. randomly 
allocated 55 cases with ischemic and non-ischemic cardiomyopathy 
(NYHA functional Classes II–IV) to trimetazidine or placebo 
administration besides conventional HF treatment. A mean follow-up 
for 13 months demonstrated that the trimetazidine recipients showed 
remarkable improvement in exercise capacity, and LVEF, and a decrease 
in end-systolic volume of LV in contrast to placebo group. Trimetazidine 
administered cases showed no increase in adverse events [75].
Ranolazine
Ranolazine alters the transcellular late sodium flow which results in 
decrease in overload of intracellular calcium [76]. It also involved in the 
oxidation of glucose and a decrease in FFA oxidation with a prominent 
decrease in ischemia as well as angina [77]. In cardiac failure cases with 
normal EF, changes in echocardiographic features of diastolic HF are 
being evaluated in a minor clinical study [78].
L-carnitine
L-carnitine is an essential cofactor in FFA metabolism. It prevents 
the accumulation of FFA, prevents generation of lactic acid, and also 
increases utilization of glucose [79]. L-carnitine deficiency is associated 
with cardiomyopathy [80]. In HF patients, acute administration 
of propionyl l-carnitine (IV bolus, 30 mg/kg body weight) showed 
reduction in pulmonary artery pressure and also pulmonary capillary 
wedge pressure. Propionyl-L-carnitine increases exercise capacity and 
reduces ventricular size in patients with CHF [81].
SACUBITRIL+VALSARTAN
It is a combination drug consisting of two antihypertensives (blood 
pressure lowering drugs) in a 1:1 mixture by molecule count. The 
combination is often described as a dual-acting angiotensin receptor-
neprilysin inhibitor although the two effects are achieved by two 
different molecules [82]. It is approved as a treatment to reduce the risk 
for cardiovascular death and hospitalization in patients with chronic HF 
(NYHA Class II-IV) associated with reduced EF [83]. Valsartan is ARB 
and sacubitril is a prodrug that is activated to LBQ657 by de-ethylation 
through esterases which inhibits the enzyme neprilysin which causes 
degradation of atrial and brain natriuretic peptide. Thus, both the blood 
pressure lowering peptides work mainly by reducing blood volume. The 
double-blind study for this combination of two drugs is the largest ever 
of a HF treatment and involved 8,842 patients in 47 countries who were 
followed for 27 months. Results from the clinical trial showed : (a) 20% 
reduction in cardiovascular-associated mortality, (b) 21% decrease in 
risk associated with HF hospitalization, and (c) 16% decrease in all-
cause mortality [84]. 
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